ロード中...
Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient
BACKGROUND: In the field of breast cancer tumor biology, triple-negative breast cancer patients are the main focus of current clinical trials exploring the use of immune checkpoint inhibitors due to higher frequencies of somatic mutations, neoantigens, and resulting tumor-specific T-cell reactivity....
保存先:
| 出版年: | Breast Care (Basel) |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
S. Karger GmbH
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6465703/ https://ncbi.nlm.nih.gov/pubmed/31019444 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000492580 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|